Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

PKM2 is not required for pancreatic ductal adenocarcinoma.

Hillis AL, Lau AN, Devoe CX, Dayton TL, Danai LV, Di Vizio D, Vander Heiden MG.

Cancer Metab. 2018 Oct 23;6:17. doi: 10.1186/s40170-018-0188-1. eCollection 2018.

2.

Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.

Dexter JP, Ward PS, Dasgupta T, Hosios AM, Gunawardena J, Vander Heiden MG.

J Biol Chem. 2018 Oct 31. pii: jbc.RA118.004278. doi: 10.1074/jbc.RA118.004278. [Epub ahead of print]

3.

Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth.

Cox AG, Tsomides A, Yimlamai D, Hwang KL, Miesfeld J, Galli GG, Fowl BH, Fort M, Ma KY, Sullivan MR, Hosios AM, Snay E, Yuan M, Brown KK, Lien EC, Chhangawala S, Steinhauser ML, Asara JM, Houvras Y, Link B, Vander Heiden MG, Camargo FD, Goessling W.

EMBO J. 2018 Nov 15;37(22). pii: e100294. doi: 10.15252/embj.2018100294. Epub 2018 Oct 22.

PMID:
30348863
4.

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.

McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, Shank K, Rapaport FT, Patel MA, Papalexi E, Shih AH, Chiu A, Freinkman E, Akbay EA, Steadman M, Nagaraja R, Yen K, Teruya-Feldstein J, Wong KK, Rampal R, Vander Heiden MG, Thompson CB, Levine RL.

J Clin Invest. 2018 Oct 1;128(10):4743. doi: 10.1172/JCI124920. Epub 2018 Sep 17. No abstract available.

5.

Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma.

McBrayer SK, Mayers JR, DiNatale GJ, Shi DD, Khanal J, Chakraborty AA, Sarosiek KA, Briggs KJ, Robbins AK, Sewastianik T, Shareef SJ, Olenchock BA, Parker SJ, Tateishi K, Spinelli JB, Islam M, Haigis MC, Looper RE, Ligon KL, Bernstein BE, Carrasco RD, Cahill DP, Asara JM, Metallo CM, Yennawar NH, Vander Heiden MG, Kaelin WG Jr.

Cell. 2018 Sep 20;175(1):101-116.e25. doi: 10.1016/j.cell.2018.08.038. Epub 2018 Sep 13.

PMID:
30220459
6.

Cytosolic Aspartate Availability Determines Cell Survival When Glutamine Is Limiting.

Alkan HF, Walter KE, Luengo A, Madreiter-Sokolowski CT, Stryeck S, Lau AN, Al-Zoughbi W, Lewis CA, Thomas CJ, Hoefler G, Graier WF, Madl T, Vander Heiden MG, Bogner-Strauss JG.

Cell Metab. 2018 Nov 6;28(5):706-720.e6. doi: 10.1016/j.cmet.2018.07.021. Epub 2018 Aug 16.

PMID:
30122555
7.

Microenvironmental regulation of cancer cell metabolism: implications for experimental design and translational studies.

Muir A, Danai LV, Vander Heiden MG.

Dis Model Mech. 2018 Aug 7;11(8). pii: dmm035758. doi: 10.1242/dmm.035758. Review.

8.

Serine Synthesis via PHGDH Is Essential for Heme Production in Endothelial Cells.

Vandekeere S, Dubois C, Kalucka J, Sullivan MR, García-Caballero M, Goveia J, Chen R, Diehl FF, Bar-Lev L, Souffreau J, Pircher A, Kumar S, Vinckier S, Hirabayashi Y, Furuya S, Schoonjans L, Eelen G, Ghesquière B, Keshet E, Li X, Vander Heiden MG, Dewerchin M, Carmeliet P.

Cell Metab. 2018 Oct 2;28(4):573-587.e13. doi: 10.1016/j.cmet.2018.06.009. Epub 2018 Jul 12.

PMID:
30017355
9.

Aspartate is an endogenous metabolic limitation for tumour growth.

Sullivan LB, Luengo A, Danai LV, Bush LN, Diehl FF, Hosios AM, Lau AN, Elmiligy S, Malstrom S, Lewis CA, Vander Heiden MG.

Nat Cell Biol. 2018 Jul;20(7):782-788. doi: 10.1038/s41556-018-0125-0. Epub 2018 Jun 25.

PMID:
29941931
10.

Altered exocrine function can drive adipose wasting in early pancreatic cancer.

Danai LV, Babic A, Rosenthal MH, Dennstedt EA, Muir A, Lien EC, Mayers JR, Tai K, Lau AN, Jones-Sali P, Prado CM, Petersen GM, Takahashi N, Sugimoto M, Yeh JJ, Lopez N, Bardeesy N, Fernandez-Del Castillo C, Liss AS, Koong AC, Bui J, Yuan C, Welch MW, Brais LK, Kulke MH, Dennis C, Clish CB, Wolpin BM, Vander Heiden MG.

Nature. 2018 Jun;558(7711):600-604. doi: 10.1038/s41586-018-0235-7. Epub 2018 Jun 20.

PMID:
29925948
11.

Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma.

Dayton TL, Gocheva V, Miller KM, Bhutkar A, Lewis CA, Bronson RT, Vander Heiden MG, Jacks T.

Cancer Metab. 2018 May 31;6:6. doi: 10.1186/s40170-018-0179-2. eCollection 2018.

12.

The nutrient environment affects therapy.

Muir A, Vander Heiden MG.

Science. 2018 Jun 1;360(6392):962-963. doi: 10.1126/science.aar5986. No abstract available.

PMID:
29853672
13.

Protocols for Studies on TMPRSS2/ERG in Prostate Cancer.

Pakula H, Linn DE, Schmidt DR, Van Gorsel M, Vander Heiden MG, Li Z.

Methods Mol Biol. 2018;1786:131-151. doi: 10.1007/978-1-4939-7845-8_8.

PMID:
29786791
14.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

15.

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.

McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, Shank K, Rapaport FT, Patel MA, Papalexi E, Shih AH, Chiu A, Freinkman E, Akbay EA, Steadman M, Nagaraja R, Yen K, Teruya-Feldstein J, Wong KK, Rampal R, Vander Heiden MG, Thompson CB, Levine RL.

J Clin Invest. 2018 Feb 1;128(2):789-804. doi: 10.1172/JCI94516. Epub 2018 Jan 22.

16.

The redox requirements of proliferating mammalian cells.

Hosios AM, Vander Heiden MG.

J Biol Chem. 2018 May 18;293(20):7490-7498. doi: 10.1074/jbc.TM117.000239. Epub 2018 Jan 16. Review.

PMID:
29339555
17.

PKM2 is not required for colon cancer initiated by APC loss.

Lau AN, Israelsen WJ, Roper J, Sinnamon MJ, Georgeon L, Dayton TL, Hillis AL, Yilmaz OH, Di Vizio D, Hung KE, Vander Heiden MG.

Cancer Metab. 2017 Nov 30;5:10. doi: 10.1186/s40170-017-0172-1. eCollection 2017.

18.

Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer.

Graff RE, Ahearn TU, Pettersson A, Ebot EM, Gerke T, Penney KL, Wilson KM, Markt SC, Pernar CH, Gonzalez-Feliciano AG, Song M, Lis RT, Schmidt DR, Vander Heiden MG, Fiorentino M, Giovannucci EL, Loda M, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):193-200. doi: 10.1158/1055-9965.EPI-17-0547. Epub 2017 Nov 22.

PMID:
29167279
19.

mTORC1 Activator SLC38A9 Is Required to Efflux Essential Amino Acids from Lysosomes and Use Protein as a Nutrient.

Wyant GA, Abu-Remaileh M, Wolfson RL, Chen WW, Freinkman E, Danai LV, Vander Heiden MG, Sabatini DM.

Cell. 2017 Oct 19;171(3):642-654.e12. doi: 10.1016/j.cell.2017.09.046.

20.

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.

Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, Sánchez-Rivera FJ, Subbaraj L, Martinez B, Bronson RT, Prigge JR, Schmidt EE, Thomas CJ, Goparaju C, Davies A, Dolgalev I, Heguy A, Allaj V, Poirier JT, Moreira AL, Rudin CM, Pass HI, Vander Heiden MG, Jacks T, Papagiannakopoulos T.

Nat Med. 2017 Nov;23(11):1362-1368. doi: 10.1038/nm.4407. Epub 2017 Oct 2.

21.

Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer.

Sayin VI, LeBoeuf SE, Singh SX, Davidson SM, Biancur D, Guzelhan BS, Alvarez SW, Wu WL, Karakousi TR, Zavitsanou AM, Ubriaco J, Muir A, Karagiannis D, Morris PJ, Thomas CJ, Possemato R, Vander Heiden MG, Papagiannakopoulos T.

Elife. 2017 Oct 2;6. pii: e28083. doi: 10.7554/eLife.28083.

22.

Targeting Metabolism for Cancer Therapy.

Luengo A, Gui DY, Vander Heiden MG.

Cell Chem Biol. 2017 Sep 21;24(9):1161-1180. doi: 10.1016/j.chembiol.2017.08.028. Review.

23.

Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition.

Muir A, Danai LV, Gui DY, Waingarten CY, Lewis CA, Vander Heiden MG.

Elife. 2017 Aug 15;6. pii: e27713. doi: 10.7554/eLife.27713.

24.

Metabolism and Congenital Malformations - NAD's Effects on Development.

Vander Heiden MG.

N Engl J Med. 2017 Aug 10;377(6):509-511. doi: 10.1056/NEJMp1707487. No abstract available.

PMID:
28792881
25.

Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer.

Ebot EM, Gerke T, Labbé DP, Sinnott JA, Zadra G, Rider JR, Tyekucheva S, Wilson KM, Kelly RS, Shui IM, Loda M, Kantoff PW, Finn S, Vander Heiden MG, Brown M, Giovannucci EL, Mucci LA.

Cancer. 2017 Nov 1;123(21):4130-4138. doi: 10.1002/cncr.30831. Epub 2017 Jul 12.

26.

Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions.

Olivares O, Mayers JR, Gouirand V, Torrence ME, Gicquel T, Borge L, Lac S, Roques J, Lavaut MN, Berthezène P, Rubis M, Secq V, Garcia S, Moutardier V, Lombardo D, Iovanna JL, Tomasini R, Guillaumond F, Vander Heiden MG, Vasseur S.

Nat Commun. 2017 Jul 7;8:16031. doi: 10.1038/ncomms16031.

27.

Nature and Nurture: What Determines Tumor Metabolic Phenotypes?

Mayers JR, Vander Heiden MG.

Cancer Res. 2017 Jun 15;77(12):3131-3134. doi: 10.1158/0008-5472.CAN-17-0165. Epub 2017 Jun 5. Review.

28.

Pyruvate Kinase Inhibits Proliferation during Postnatal Cerebellar Neurogenesis and Suppresses Medulloblastoma Formation.

Tech K, Tikunov AP, Farooq H, Morrissy AS, Meidinger J, Fish T, Green SC, Liu H, Li Y, Mungall AJ, Moore RA, Ma Y, Jones SJM, Marra MA, Vander Heiden MG, Taylor MD, Macdonald JM, Gershon TR.

Cancer Res. 2017 Jun 15;77(12):3217-3230. doi: 10.1158/0008-5472.CAN-16-3304. Epub 2017 May 17.

29.

Biochemical Underpinnings of Immune Cell Metabolic Phenotypes.

Olenchock BA, Rathmell JC, Vander Heiden MG.

Immunity. 2017 May 16;46(5):703-713. doi: 10.1016/j.immuni.2017.04.013. Review.

30.

Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction.

Qi W, Keenan HA, Li Q, Ishikado A, Kannt A, Sadowski T, Yorek MA, Wu IH, Lockhart S, Coppey LJ, Pfenninger A, Liew CW, Qiang G, Burkart AM, Hastings S, Pober D, Cahill C, Niewczas MA, Israelsen WJ, Tinsley L, Stillman IE, Amenta PS, Feener EP, Vander Heiden MG, Stanton RC, King GL.

Nat Med. 2017 Jun;23(6):753-762. doi: 10.1038/nm.4328. Epub 2017 Apr 24.

31.

When cancer needs what's non-essential.

Sullivan MR, Vander Heiden MG.

Nat Cell Biol. 2017 May;19(5):418-420. doi: 10.1038/ncb3523. Epub 2017 Apr 19.

PMID:
28422952
32.

Understanding the Intersections between Metabolism and Cancer Biology.

Vander Heiden MG, DeBerardinis RJ.

Cell. 2017 Feb 9;168(4):657-669. doi: 10.1016/j.cell.2016.12.039. Review.

33.

Endothelial Cells Get β-ox-ed In to Support Lymphangiogenesis.

Hosios AM, Vander Heiden MG.

Dev Cell. 2017 Jan 23;40(2):118-119. doi: 10.1016/j.devcel.2017.01.004.

34.

Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.

Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ.

J Gastrointest Oncol. 2016 Dec;7(6):819-827. doi: 10.21037/jgo.2016.11.11. No abstract available.

35.

Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors.

Davidson SM, Jonas O, Keibler MA, Hou HW, Luengo A, Mayers JR, Wyckoff J, Del Rosario AM, Whitman M, Chin CR, Condon KJ, Lammers A, Kellersberger KA, Stall BK, Stephanopoulos G, Bar-Sagi D, Han J, Rabinowitz JD, Cima MJ, Langer R, Vander Heiden MG.

Nat Med. 2017 Feb;23(2):235-241. doi: 10.1038/nm.4256. Epub 2016 Dec 26.

36.

PKM2, cancer metabolism, and the road ahead.

Dayton TL, Jacks T, Vander Heiden MG.

EMBO Rep. 2016 Dec;17(12):1721-1730. Epub 2016 Nov 17. Review.

37.

Corrigendum: A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect.

Lopez-Serra P, Marcilla M, Villanueva A, Ramos-Fernandez A, Palau A, Leal L, Wahi JE, Setien-Baranda F, Szczesna K, Moutinho C, Martinez-Cardus A, Heyn H, Sandoval J, Puertas S, Vidal A, Sanjuan X, Martinez-Balibrea E, Viñals F, Perales JC, Bramsem JB, Ørntoft TF, Andersen CL, Tabernero J, McDermott U, Boxer MB, Vander Heiden MG, Albar JP, Esteller M.

Nat Commun. 2016 Nov 2;7:13467. doi: 10.1038/ncomms13467. No abstract available.

38.

Altered metabolite levels in cancer: implications for tumour biology and cancer therapy.

Sullivan LB, Gui DY, Vander Heiden MG.

Nat Rev Cancer. 2016 Nov;16(11):680-693. doi: 10.1038/nrc.2016.85. Epub 2016 Sep 23. Review.

PMID:
27658530
39.

Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin.

Gui DY, Sullivan LB, Luengo A, Hosios AM, Bush LN, Gitego N, Davidson SM, Freinkman E, Thomas CJ, Vander Heiden MG.

Cell Metab. 2016 Nov 8;24(5):716-727. doi: 10.1016/j.cmet.2016.09.006. Epub 2016 Oct 13.

40.

Critical Functions of the Lysosome in Cancer Biology.

Davidson SM, Vander Heiden MG.

Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:481-507. doi: 10.1146/annurev-pharmtox-010715-103101. Epub 2016 Oct 12. Review.

PMID:
27732799
41.

Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers.

Mayers JR, Torrence ME, Danai LV, Papagiannakopoulos T, Davidson SM, Bauer MR, Lau AN, Ji BW, Dixit PD, Hosios AM, Muir A, Chin CR, Freinkman E, Jacks T, Wolpin BM, Vitkup D, Vander Heiden MG.

Science. 2016 Sep 9;353(6304):1161-5. doi: 10.1126/science.aaf5171.

42.

Metabolic requirements for cancer cell proliferation.

Keibler MA, Wasylenko TM, Kelleher JK, Iliopoulos O, Vander Heiden MG, Stephanopoulos G.

Cancer Metab. 2016 Aug 18;4:16. doi: 10.1186/s40170-016-0156-6. eCollection 2016.

43.

Circadian Rhythm Disruption Promotes Lung Tumorigenesis.

Papagiannakopoulos T, Bauer MR, Davidson SM, Heimann M, Subbaraj L, Bhutkar A, Bartlebaugh J, Vander Heiden MG, Jacks T.

Cell Metab. 2016 Aug 9;24(2):324-31. doi: 10.1016/j.cmet.2016.07.001. Epub 2016 Jul 28.

44.

The importance of serine metabolism in cancer.

Mattaini KR, Sullivan MR, Vander Heiden MG.

J Cell Biol. 2016 Aug 1;214(3):249-57. doi: 10.1083/jcb.201604085. Epub 2016 Jul 25. Review.

45.

InterFeriNg with Acetγlation: Stress-Levels of Acetate Improve Memory T Cell Function.

Lewis CA, Vander Heiden MG.

Immunity. 2016 Jun 21;44(6):1243-5. doi: 10.1016/j.immuni.2016.06.004.

46.

Targeting MTHFD2 in acute myeloid leukemia.

Pikman Y, Puissant A, Alexe G, Furman A, Chen LM, Frumm SM, Ross L, Fenouille N, Bassil CF, Lewis CA, Ramos A, Gould J, Stone RM, DeAngelo DJ, Galinsky I, Clish CB, Kung AL, Hemann MT, Vander Heiden MG, Banerji V, Stegmaier K.

J Exp Med. 2016 Jun 27;213(7):1285-306. doi: 10.1084/jem.20151574. Epub 2016 Jun 20.

47.

Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.

Kelly RS, Vander Heiden MG, Giovannucci E, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2016 Jun;25(6):887-906. doi: 10.1158/1055-9965.EPI-15-1223. Epub 2016 Apr 6. Review.

48.

Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma.

Dayton TL, Gocheva V, Miller KM, Israelsen WJ, Bhutkar A, Clish CB, Davidson SM, Luengo A, Bronson RT, Jacks T, Vander Heiden MG.

Genes Dev. 2016 May 1;30(9):1020-33. doi: 10.1101/gad.278549.116. Epub 2016 Apr 28.

49.

A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.

Pacold ME, Brimacombe KR, Chan SH, Rohde JM, Lewis CA, Swier LJ, Possemato R, Chen WW, Sullivan LB, Fiske BP, Cho S, Freinkman E, Birsoy K, Abu-Remaileh M, Shaul YD, Liu CM, Zhou M, Koh MJ, Chung H, Davidson SM, Luengo A, Wang AQ, Xu X, Yasgar A, Liu L, Rai G, Westover KD, Vander Heiden MG, Shen M, Gray NS, Boxer MB, Sabatini DM.

Nat Chem Biol. 2016 Jun;12(6):452-8. doi: 10.1038/nchembio.2070. Epub 2016 Apr 25. Erratum in: Nat Chem Biol. 2016 Jul 19;12 (8):656.

50.

EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection.

Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Chakraborty AA, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG Jr.

Cell. 2016 Apr 7;165(2):497. doi: 10.1016/j.cell.2016.03.037. No abstract available.

Supplemental Content

Loading ...
Support Center